Hosted on MSN16d
GSK buys US-based rare cancer treatment developer for up to £1bn
according to the American Cancer Society. GSK’s acquisition of IDRx will include IDRX-42 which is currently being developed and trialled as therapy for the treatment of gastrointestinal stomal ...
Demand for Advanced Pancreatic Cancer Treatments at All Time High as Promising Options Come into Focus
The aging population and lifestyle-related factors contribute to a surge in pancreatic cancer cases. The aggressive nature of the disease and its high mortality rate demand innovative therapies.
Nasdaq7d
Demand for Advanced Pancreatic Cancer Treatments at All Time High as Promising Options Come into Focus
Pancreatic cancer remains a formidable foe, with the American Cancer Society estimating over 66,000 ... ONCY) (TSX: ONC), GSK plc (NYSE: GSK), AstraZeneca PLC (NASDAQ: AZN), Gilead Sciences ...